Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs.
The antiallergic drug repirinast (30 mg/kg i.p.) significantly inhibited antigen-induced early and late pulmonary responses in guinea pigs. The same dose of repirinast significantly inhibited bronchoalveolar lavage eosinophilia and neutrophilia 5 h after antigen challenge (at the peak of the late response). Histologic examination revealed that repirinast markedly inhibited leukocyte (predominantly eosinophils) infiltration into bronchial tissue. Repirinast also blocked antigen-induced airway hyperresponsiveness to inhaled acetylcholine. The inhibitory effect of repirinast on the infiltration of eosinophils and/or neutrophils into the airway may reflect the inhibition of late pulmonary response and airway hyperresponsiveness.
Yamada
N
N
Pharmaceuticals Laboratory, Mitsubishi Kasei Corp., Yokohama, Japan.
Ohgaki
M
M
Muramatsu
M
M
D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016084:Bronchoconstriction / Q000187:drug effects; D006168:Guinea Pigs; D007958:Leukocyte Count / Q000187:drug effects; D008168:Lung / Q000503:physiopathology; D008297:Male; D015363:Quinolones / Q000494:pharmacology*; D013997:Time Factors
D015363:Quinolones; C048522:repirinast